Across TCGA pan-cancer cohorts, TLL2 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of TLL2’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where TLL2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TLL2 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.
LSCC are the cancer types where TLL2 tumor–normal differential expression is most reproducible.